MX2021009670A - Tratamiento para el cancer. - Google Patents

Tratamiento para el cancer.

Info

Publication number
MX2021009670A
MX2021009670A MX2021009670A MX2021009670A MX2021009670A MX 2021009670 A MX2021009670 A MX 2021009670A MX 2021009670 A MX2021009670 A MX 2021009670A MX 2021009670 A MX2021009670 A MX 2021009670A MX 2021009670 A MX2021009670 A MX 2021009670A
Authority
MX
Mexico
Prior art keywords
cancer treatment
cancer
treatment
erdafitinib
provides
Prior art date
Application number
MX2021009670A
Other languages
English (en)
Inventor
Porre Peter Marie Z De
Anjali Narayan Avadhani
Anne Elizabeth O''hagan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021009670A publication Critical patent/MX2021009670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para el tratamiento del cáncer con erdafitinib en pacientes de alto riesgo.
MX2021009670A 2019-02-12 2020-02-11 Tratamiento para el cancer. MX2021009670A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19176575 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Publications (1)

Publication Number Publication Date
MX2021009670A true MX2021009670A (es) 2021-09-08

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009670A MX2021009670A (es) 2019-02-12 2020-02-11 Tratamiento para el cancer.

Country Status (15)

Country Link
US (1) US20220168298A1 (es)
EP (1) EP3923942A1 (es)
JP (1) JP2022521173A (es)
KR (1) KR20210126654A (es)
CN (1) CN113423402A (es)
AU (1) AU2020223467A1 (es)
BR (1) BR112021015686A2 (es)
CA (1) CA3126959A1 (es)
IL (1) IL285466A (es)
JO (1) JOP20210216A1 (es)
MA (1) MA54932A (es)
MX (1) MX2021009670A (es)
SG (1) SG11202107850VA (es)
TW (1) TW202045173A (es)
WO (1) WO2020165181A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021396397A1 (en) * 2020-12-11 2023-07-27 Erasca, Inc. Combination therapies for the treatment of cancer
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
TWI798199B (zh) * 2017-02-06 2023-04-11 比利時商健生藥品公司 癌症治療
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
SG11202107850VA (en) 2021-08-30
EP3923942A1 (en) 2021-12-22
AU2020223467A1 (en) 2021-08-05
WO2020165181A1 (en) 2020-08-20
IL285466A (en) 2021-09-30
JOP20210216A1 (ar) 2023-01-30
CA3126959A1 (en) 2020-08-20
KR20210126654A (ko) 2021-10-20
CN113423402A (zh) 2021-09-21
US20220168298A1 (en) 2022-06-02
BR112021015686A2 (pt) 2021-10-26
JP2022521173A (ja) 2022-04-06
TW202045173A (zh) 2020-12-16
MA54932A (fr) 2021-12-22

Similar Documents

Publication Publication Date Title
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EP3867410A4 (en) METHODS OF DETERMINING A TREATMENT FOR CANCER PATIENTS
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
WO2018136617A3 (en) Bacteria for treating cancer
EA201991818A1 (ru) Лечение рака
GB201903546D0 (en) Cancer treatment
MX2020008195A (es) Compuestos para el tratamiento del dolor.
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
TN2019000211A1 (en) Antitumoral compounds
ZA202206743B (en) Therapy for the treatment of cancer
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL287652A (en) Cancer treatment
IL281439A (en) Combined treatment for blood cancer
IL284162A (en) Integrated healing for cancer treatment
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2021009670A (es) Tratamiento para el cancer.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2017016346A (es) Metodos de tratamiento con taselisib.
MX2020012964A (es) Metodos para el tratamiento de cancer de vejiga.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
IL288035A (en) Cancer treatment